IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	**Re: Docket Nos. 122, 290, 397, 399, 425, 426 & 468**

FIRST NOTICE OF PREVIOUSLY OMITTED CONTRACTS DESIGNATED AS ASSIGNED CONTRACTS IN CONNECTION WITH FABRY SALE TRANSACTION

PLEASE TAKE NOTICE OF THE FOLLOWING

On September 2, 2026, the United States Bankruptcy Court for the District of Delaware (the "**Court**") entered the *Order (A) Authorizing the Sale of the Debtor's Assets Free and Clear of All Liens, Claims, Interests, and Encumbrances; (B) Approving Assumption and Assignment of the Assigned Contracts; and (C) Granting Related Relief* [Docket No. 426] (the "**Fabry Sale Order**").[2] The Fabry Sale Order, among other things: (i) authorized Sangamo Therapeutics, Inc., the above-captioned debtor and debtor in possession (the "**Debtor**"), to enter into that certain *Asset Purchase Agreement* (the "**Fabry Purchase Agreement**") pursuant to which the Debtor agreed to sell (the "**Fabry Sale Transaction**") the assets described in the Fabry Purchase Agreement to PTC Therapeutics, Inc. ("**PTC**"), (ii) authorized and approved the assumption and assignment of certain executory contracts (the "**Assigned Contracts**") in connection with the Fabry Sale Transaction, and (iii) authorized the Debtor to take all actions necessary to consummate the Fabry Sale Transaction.

The Fabry Sale Transaction closed on September 17, 2026 (the "**Closing Date**").

Pursuant to paragraph 35 of the Fabry Sale Order, prior to the Closing Date, PTC designated certain Previously Omitted Contracts to be Assigned Contracts (the "**Designated Assigned Contracts**"). Attached hereto as **Exhibit A** is a list of the Designated Assigned Contracts to be assumed and assigned to PTC in connection with the Fabry Sale Transaction, together with the Debtor's calculation of Cure Costs (if any) with respect to such Designated Assigned Contracts. The inclusion of any Designated Assigned Contracts on **Exhibit A** does not (i) constitute an admission by the Debtor, PTC, or any other party that such Designated Assigned Contracts are executory contracts or unexpired leases within the meaning of the Bankruptcy Code or (ii) require or guarantee that such Designated Assigned Contracts ultimately will be assumed or assigned. All rights of the Debtor with respect thereto are reserved.

[1] The Debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The Debtor's mailing address is 7000 Marina Blvd, Brisbane, CA 94005.

[2] Capitalized terms used but not defined herein have the meanings given to them in the Fabry Sale Order.

2610989260918000000000009

In addition, to the extent that any of the Cure Costs (if any) set forth on **Exhibit A** do not reflect (i) postpetition payments that have been made by the Debtor with respect to applicable Cure Costs (if any) or (ii) any payments that are made by the Debtor with respect to such Cure Costs (if any) after the filing of this notice, the respective amounts required to be paid to cure any existing defaults under the applicable Designated Assigned Contracts shall be reduced by any such corresponding postpetition payments, and the Debtor reserves its rights to update the Cure Costs (if any) set forth on **Exhibit A** accordingly, either by filing a supplemental notice with the Court or by written notice to the applicable counterparty.

Pursuant to paragraph 35 of the Fabry Sale Order, any counterparty to a Designated Assigned Contract that wishes to object to the assumption and assignment of such Designated Assigned Contract to PTC (including, without limitation, PTC's proposed form of adequate assurance of future performance) and the associated Cure Costs (if any) with respect to such Designated Assigned Contract (each such objection, an "**Adequate Assurance/Cure Objection**") must file its Adequate Assurance/Cure Objection with the Court by no later than **September 30, 2026, at 4:00 p.m. (Eastern Time**), which must be in writing and state, with specificity, the legal and factual bases thereof and the amount the counterparty believes to be the correct Cure Cost if objecting to any associated Cure Cost, and include any appropriate documentation in support thereof.

IF A COUNTERPARTY TO A DESIGNATED ASSIGNED CONTRACT FAILS TO FILE WITH THE COURT A TIMELY ADEQUATE ASSURANCE/CURE OBJECTION, THEN THE COUNTERPARTY: (A) SHALL BE FOREVER BARRED, ESTOPPED AND ENJOINED FROM ASSERTING (1) ANY OBJECTION TO THE ASSUMPTION AND/OR ASSIGNMENT, (2) ANY OBJECTION WITH REGARD TO THE COST TO CURE ANY DEFAULTS UNDER THE APPLICABLE DESIGANTED ASSIGNED CONTRACT, AND (3) THAT ANY CONDITIONS TO THE ASSUMPTION AND ASSIGNMENT OF SUCH DESIGNAGED ASSIGNED CONTRACT HAVE NOT BEEN SATISFIED PURSUANT TO SECTION 365(b)(1) OF THE BANKRUPTCY CODE OR OTHERWISE; (B) THE CURE COSTS SET FORTH ON EXHIBIT A HERETO SHALL BE CONTROLLING AND WILL BE THE ONLY AMOUNT NECESSARY TO CURE OUTSTANDING DEFAULTS UNDER THE DESIGNATED ASSIGNED CONTRACT AND SATISFY THE REQUIREMENTS OF SECTION 365(b) OF THE BANKRUPTCY CODE, AND THE COUNTERPARTY TO THE DESIGNATED ASSIGNED CONTRACT SHALL BE DEEMED BOUND BY AND TO HAVE CONSENTED TO THE CURE AMOUNTS; AND (C) PTC SHALL BE DEEMED TO HAVE PROVIDED ADEQUATE ASSURANCE OF FUTURE PERFORMANCE WITH RESPECT TO THE DESIGNATED ASSIGNED CONTRACTS IN ACCORDANCE WITH BANKRUPTCY CODE SECTIONS 365(b)(1)(C), 365(f)(2)(B) AND, IF APPLICABLE, 365(b)(3), NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THE DESIGNATED ASSIGNED CONTRACT.

Dated: September 18, 2026
Wilmington, Delaware

/s/ Nicholas A. Franchi

Daniel J. DeFranceschi (No. 2732)
Amanda R. Steele (No. 5530)
Brendan J. Schlauch (No. 6115)
Nicholas A. Franchi (No. 7401)
RICHARDS, LAYTON & FINGER, P.A.
One Rodney Square
920 N. King Street
Wilmington, Delaware 19801
Telephone: (302) 651-7700
Emails: defranceschi@rlf.com
steele@rlf.com
schlauch@rlf.com
franchi@rlf.com
and

Cullen D. Speckhart
Lauren A. Reichardt
Miriam Peguero Medrano
COOLEY LLP
55 Hudson Yards
New York, NY 10001-2157
Telephone: (212) 479-6000
Emails: cspeckhart@cooley.com
lreichardt@cooley.com
mpegueromedrano@cooley.com
and

Robert L. Eisenbach III
COOLEY LLP
3 Embarcadero Center, 20th Floor
San Francisco, CA 94111-4004
Telephone: (415) 693-2000
Email: reisenbach@cooley.com

Counsel for the Debtor and Debtor in Possession

Exhibit A

Designated Assigned Contracts

Contract Counterparty	Contract Description	Cure Amount[1]
Medpace Australia Pty. Ltd.	Local Sponsor Agreement dated January 11, 2021	$0.00
Medpace Germany GmbH	Assignment	$0.00
Medpace, Inc.	Termination dated May 2, 2024	$0.00
Medpace, Inc.	Confidential Disclosure Agreement dated February 22, 2017	$0.00
Medpace, Inc.	Confidential Disclosure Agreement dated June 13, 2019	$0.00
Medpace, Inc.	Clinical Study Agreement dated September 15, 2021	$0.00
Medpace, Inc.	Confidential Disclosure Agreement dated January 7, 2010	$0.00
Medpace, Inc.	Confidential Disclosure Agreement dated March 17, 2021	$0.00
Medpace, Inc.	Letter of Authorization dated October 19, 2021	$0.00
Medpace, Inc.	Letter of Intent dated June 26, 2017	$0.00
Medpace Research, Inc.	Letter of Intent dated November 27, 2018	$0.00
Medpace Research, Inc.	Amendment #1 to Letter of Intent dated February 1, 2019	$0.00
Medpace Research, Inc.	Termination dated April 5, 2022	$0.00
Medpace UK Ltd.	Non-Interventional Study Agreement	$0.00
Q-Square Business Intelligence, Inc.	Master Services Agreement dated April 27, 2020	$0.00

[1] The Cure Amounts set forth herein do not reflect postpetition payments that have been made by the Debtor. Postpetition amounts arising under the Designated Assigned Contracts will be paid in the ordinary course and not in connection with payments made to satisfy the Cure Amounts.

Contract Counterparty	Contract Description	Cure Amount[1]
Q-Square Business Intelligence, Inc.	Termination dated April 17, 2024	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work #1 dated April 27, 2020	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work #2 dated November 5, 2020	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work #9 dated January 25, 2022	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work #4 dated November 15, 2021	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work 003SD101 dated February 28, 2023	$0.00
Q-Square Business Intelligence, Inc.	Amendment #1 to MSA dated November 6, 2020	$0.00
Q-Square Business Intelligence, Inc.	Amendment #1 to MSA dated December 22, 2021	$0.00
Q-Square Business Intelligence, Inc.	Change Order #1 to Statement of Work #6 dated December 9, 2022	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work #10 dated April 22, 2022	$0.00
Q-Square Business Intelligence, Inc.	Statement of Work for ST-920 BLA dated February 7, 2025	$0.00
Bioclinica, Inc.	Confidential Disclosure Agreement dated October 5, 2017	$0.00
Bioclinica, Inc.	Non-Disclosure Agreement dated February 17, 2016	$0.00
Bioclinica, Inc.	Confidential Disclosure Agreement dated March 29, 2021	$0.00
Helmut Schweiger, Clinical Research and Project Management (CRP)	Master Services Agreement, dated May 13, 2026	$7,717.50
PCI Pharma Services	Global Clinical Services Quality (Technical) Agreement dated November 4, 2021	$0.00